When: Thursday, May 3, 2012 | 11:30 a.m. to 1:00 p.m
Where: AT&T Executive Education and Conference Center, Room 202
Cost: $20 per person. Includes box lunch
Parking: Garage parking is available at the AT&T Conference Center
REGISTER : http://bit.ly/PointOfCare
Summary: Imagine the day when you will simply spit on a piece of paper to test yourself for the flu. The possibility that simple, point-of-sale consumer diagnostics – like today's home pregnancy tests – could be mass marketed for a variety of diseases will not only change how the pharmaceutical industry delivers treatments, it may also transform the hallowed doctor-patient relationship.
Join us for lunch on May 3 to hear Dr. Andrew Ellington, a professor of Chemistry and Biochemistry at The University of Texas at Austin, describe his research using DNA computation to develop innovative point-of-care diagnostics. He will talk about how far his research has come and what the future holds.
Funded by the Bill & Melinda Gates Foundation, Dr. Ellington is developing a portable, cheap and disposable field test for tuberculosis – a strip of paper embedded with synthetic DNA. This product could be the technological basis to develop testing for other types of disease. DNA computation is, as its name implies, completely programmable and can be reconfigured for a variety of diseases. The revolutions in biotechnology and genomics over the last several decades have made DNA a relatively cheap commodity. DNA computation in point-of-care diagnostics has special advantages in developing economies countries because it takes place without enzymes, which often require electricity and refrigeration.